ImmunityBio, Inc. IBRX Remainder of Fiscal Year 2024
Remainder of Fiscal Year 2024 at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s remainder of fiscal year 2024.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is ImmunityBio, Inc.'s remainder of fiscal year 2024?
- ImmunityBio, Inc. (IBRX) reported remainder of fiscal year 2024 of $8.71M in Q1 2026.
- How has ImmunityBio, Inc.'s remainder of fiscal year 2024 changed year-over-year?
- ImmunityBio, Inc.'s remainder of fiscal year 2024 increased by 0.6% year-over-year, from $8.66M to $8.71M.